Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting
CompletedOBSERVATIONAL
Enrollment
73
Participants
Timeline
Start Date
October 1, 2019
Primary Completion Date
April 4, 2023
Study Completion Date
April 4, 2023
Conditions
Stage III MelanomaStage IV Cutaneous Melanoma
Trial Locations (1)
44195
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer center, Cleveland
All Listed Sponsors
lead
Case Comprehensive Cancer Center
OTHER
NCT05079113 - Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting | Biotech Hunter | Biotech Hunter